Imatinib Mylan Tablet, film coated 400mg Malta - English - Medicines Authority

imatinib mylan tablet, film coated 400mg

generics uk limited - imatinib - film-coated tablet - imatinib 400 mg - antineoplastic agents

Imatinib 100 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

imatinib 100 mg film-coated tablets

mcdermott laboratories ltd., t/a gerard laboratories - imatinib - film-coated tablet - 100 milligram(s) - imatinib

Imatinib 400 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

imatinib 400 mg film-coated tablets

mcdermott laboratories ltd., t/a gerard laboratories - imatinib - film-coated tablet - 400 milligram(s) - imatinib

Imatinib Mylan 100mg film-coated tablets Malta - English - Medicines Authority

imatinib mylan 100mg film-coated tablets

mylan ireland limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - imatinib - film-coated tablet - imatinib 100 mg - antineoplastic agents

Imatinib Mylan 400mg film-coated tablets Malta - English - Medicines Authority

imatinib mylan 400mg film-coated tablets

mylan ireland limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - imatinib - film-coated tablet - imatinib 400 mg - antineoplastic agents

GILMAT imatinib (as mesilate) 100 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

gilmat imatinib (as mesilate) 100 mg film-coated tablet blister pack

pharmacor pty ltd - imatinib mesilate, quantity: 119.5 mg (equivalent: imatinib, qty 100 mg) - tablet, film coated - excipient ingredients: magnesium stearate; titanium dioxide; macrogol 8000; hypromellose; purified talc - gilmat is indicated for the:,? treatment of patients with chronic myeloid leukaemia (cml),? treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy,? treatment of adult patients with relapsed or refractory ph+ all as monotherapy,? treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements, where conventional therapies have failed, ? treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel), ?treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) ?adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist (see dosage and administration and clinical trials) ? treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp).

GILMAT imatinib (as mesilate) 100 mg film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

gilmat imatinib (as mesilate) 100 mg film-coated tablet bottle

pharmacor pty ltd - imatinib mesilate, quantity: 119.5 mg (equivalent: imatinib, qty 100 mg) - tablet, film coated - excipient ingredients: magnesium stearate; titanium dioxide; macrogol 8000; hypromellose; purified talc - gilmat is indicated for the:,? treatment of patients with chronic myeloid leukaemia (cml) ? treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy ? treatment of adult patients with relapsed or refractory ph+ all as monotherapy ? treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements, where conventional therapies have failed ? treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) ?treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) ?adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist (see dosage and administration and clinical trials) ? treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp).

Imatinib Siegfried 100mg film-coated Tablets Malta - English - Medicines Authority

imatinib siegfried 100mg film-coated tablets

kohne pharma gmbh - imatinib 100 mg - film-coated tablet

Imatinib Siegfried 400mg film-coated Tablets Malta - English - Medicines Authority

imatinib siegfried 400mg film-coated tablets

kohne pharma gmbh - imatinib 400 mg - film-coated tablet

Imatinib Rowex 100mg Film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

imatinib rowex 100mg film-coated tablets

rowex ltd - imatinib mesilate - film-coated tablet - 100 milligram(s) - protein kinase inhibitors; imatinib - protein-tyrosine kinase inhibitor - paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult patients with ph+ cml in blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement. adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurre